BiomX (PHGE) Shares Outstanding (2018 - 2026)
BiomX (PHGE) posted Shares Outstanding (Entity) of $2.6 million for Q1 2026, up 63.38% sequentially from $1.6 million in Q4 2025, and up 98.16% YoY from $1.3 million in Q1 2025.
BiomX (PHGE) Shares Outstanding (2018 - 2026) Analysis & Trends
BiomX has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $2.6 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 98.16% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (up 98.16% YoY) and the FY2025 annual result came in at $1.6 million, up 151.94% from the prior year.
- Shares Outstanding (Entity) grew to $2.6 million in Q1 2026 per PHGE's latest filing, from $1.6 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $2.6 million in Q1 2026 and troughed at $156704.0 in Q1 2022.
- A 5-year average of $732129.4 and a median of $367391.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) grew 0.77% in 2022, then jumped 278.81% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $157767.0 in 2022, then jumped by 53.39% to $241992.0 in 2023, then surged by 161.41% to $632581.0 in 2024, then soared by 151.94% to $1.6 million in 2025, then surged by 63.38% to $2.6 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $2.6 million, $1.6 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.60 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | 632,581.00 |
| Sep 30, 2024 | 861,349.00 |
| Jun 30, 2024 | 367,407.00 |
| Mar 15, 2024 | 270,151.00 |
| Dec 31, 2023 | 270,151.00 |
| Sep 30, 2023 | 318,873.00 |
| Jun 30, 2023 | 271,323.00 |
| Mar 31, 2023 | 169,075.00 |
| Dec 31, 2022 | 157,122.00 |
| Sep 30, 2022 | 157,405.00 |
| Jun 30, 2022 | 156,704.00 |
| Mar 31, 2022 | 156,597.00 |
| Dec 31, 2021 | 136,880.00 |
| Sep 30, 2021 | 142,511.00 |
| Jun 30, 2021 | 127,998.00 |